Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1 1

Status

Terminated 5Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 3Triple Negative Breast Neoplasms 1Lung Neoplasms 1Carcinoma 1

Interventions

Carboplatin 103Pemetrexed 96pembrolizumab 78Docetaxel 78Cisplatin 72Paclitaxel 70Erlotinib Hydrochloride 50Gemcitabine 48Radiotherapy 42Nivolumab 35Bevacizumab 35atezolizumab 24Radiosurgery 24durvalumab 20Cyclophosphamide 17130-nm albumin-bound paclitaxel 15Vinorelbine 14Taxes 14Radiation 14Etoposide 13Ipilimumab 12Albumin-Bound Paclitaxel 12avelumab 11Drug Therapy 10Cetuximab 10spartalizumab 9Sorafenib 9trametinib 8osimertinib 8capmatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Non-Small-Cell Lung × canakinumab × Clear all
NCT03631199 2026-02-25

CANOPY-1

Novartis

Phase 3 Terminated
673 enrolled 38 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03447769 2024-10-09

Canopy-A

Novartis

Phase 3 Terminated
1,382 enrolled 23 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03968419 2024-06-20

CANOPY-N

Novartis

Phase 2 Terminated
88 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03626545 2023-08-21

CANOPY-2

Novartis

Phase 3 Terminated
245 enrolled 29 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Novartis

Phase 1 Terminated
111 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡